Marksans Pharma Ltd
MARKSANSMarksans Pharma Ltd
MARKSANS![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
29.04 | 5.16 | 0.30% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 902.20 | 774.18 | 921.16 | 1,004.69 | 1,134.54 | 1,382.87 | 1,532.69 | 1,911.45 | 2,227.83 | 2,227.83 | ||||||||||
Raw Materials | 504.85 | 506.68 | 502.58 | 517.91 | 514.88 | 731.33 | 703.92 | 927.75 | 1,718.83 | 1,718.84 | ||||||||||
Power & Fuel Cost | 12.58 | 12.97 | 11.55 | 13.99 | 14.00 | 16.42 | 18.59 | 24.50 | ||||||||||||
Employee Cost | 122.42 | 149.70 | 147.75 | 159.07 | 168.42 | 197.32 | 220.30 | 239.37 | ||||||||||||
Selling & Administrative Expenses | 65.78 | 65.18 | 88.83 | 109.58 | 120.38 | 154.55 | 148.41 | 144.74 | ||||||||||||
Operating & Other expenses | 51.43 | -12.12 | 83.60 | 67.38 | 124.28 | -63.05 | 140.74 | 176.46 | ||||||||||||
EBITDA | 145.14 | 51.77 | 86.85 | 136.76 | 192.58 | 346.30 | 300.73 | 398.63 | 509.00 | 508.99 | ||||||||||
Depreciation/Amortization | 28.13 | 30.09 | 26.84 | 22.80 | 26.66 | 36.15 | 44.78 | 51.85 | 74.27 | 74.27 | ||||||||||
PBIT | 117.01 | 21.68 | 60.01 | 113.96 | 165.92 | 310.15 | 255.95 | 346.78 | 434.73 | 434.72 | ||||||||||
Interest & Other Items | 10.16 | 6.78 | 10.22 | 9.66 | 8.75 | 7.99 | 8.45 | 9.13 | 11.20 | 11.21 | ||||||||||
PBT | 106.85 | 14.90 | 49.79 | 104.30 | 157.17 | 302.16 | 247.50 | 337.65 | 423.53 | 423.51 | ||||||||||
Taxes & Other Items | 28.33 | 6.06 | 16.86 | 27.84 | 36.42 | 66.22 | 62.95 | 71.34 | 109.83 | 109.81 | ||||||||||
Net Income | 78.52 | 8.84 | 32.93 | 76.46 | 120.75 | 235.94 | 184.55 | 266.31 | 313.70 | 313.70 | ||||||||||
EPS | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 6.18 | 6.92 | 6.92 | ||||||||||
DPS | 0.41 | 0.05 | 0.05 | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | 0.60 | 0.50 | ||||||||||
Payout ratio | 0.21 | 0.23 | 0.06 | 0.03 | 0.03 | 0.04 | 0.06 | 0.08 | 0.09 | 0.07 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Marksans Pharma Ltd | 29.04 | 5.16 | 0.30% |
Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare MARKSANS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.46%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 3.02%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.41%
Top 5 Mutual Funds holding Marksans Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
UTI Small Cap Fund - Direct Growth Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4985% | Percentage of the fund’s portfolio invested in the stock 1.08% | Change in the portfolio weight of the stock over the last 3 months 1.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 68/99 (+21) |
UTI Aggressive Hybrid Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4259% | Percentage of the fund’s portfolio invested in the stock 0.70% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 74/111 (-8) |
UTI Large & Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2969% | Percentage of the fund’s portfolio invested in the stock 0.79% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 59/69 (-17) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
MARKSANS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.30%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.98 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 7, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Jun 7, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Dividend/Share
₹0.25
Ex DateEx Date
Aug 19, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Raymond Ltd leads gainers in ‘A’ group
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
![](https://i4.ytimg.com/vi/wN2jpm9O0LU/hqdefault.jpg)
![](https://i3.ytimg.com/vi/vxJG-XAXNc8/hqdefault.jpg)
Marksans Pharma Consolidated June 2023 Net Sales at Rs 500.03 crore, up 15.28% Y-o-Y
![](https://pocket-image-cache.com/direct?url=http://images.moneycontrol.com/static-mcnews/2017/04/shutterstock_310523045-462x435.jpg)
Marksans Pharma shares rally 9% on FDA nod to pain relief tablet
![](https://pocket-image-cache.com/direct?url=http://images.moneycontrol.com/static-mcnews/2021/04/pharma1-2-770x433.jpg)
Tata Power, Marksans Pharma, Uniparts India shares to turn ex-dividend today
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202306/chung_khoan_0-sixteen_nine.jpg)
Stocks to Watch today | Tuesday, June 7: Adani Green, Mazagon Dock, Torrent Power | Business Standard
![](https://pocket-image-cache.com/direct?url=http://bsmedia.business-standard.com/_media/bs/img/misc/2023-03/21/full/market-stocks-stock-market-trading-stock-market-1679390715-4232620.jpg)
Marksans Pharma Consolidated March 2023 Net Sales at Rs 485.98 crore, up 16.25% Y-o-Y
![](https://pocket-image-cache.com/direct?url=http://images.moneycontrol.com/static-mcnews/2017/04/shutterstock_310523045-462x435.jpg)
Marksans Pharma completes the acquisition from Tevapharm India
![](https://pocket-image-cache.com/direct?url=http://gumlet.assettype.com/freepressjournal/2023-04/9e0d02b3-5bbd-4474-b69f-a3256c0cd653/Untitled_design___2023_04_19T115617_798.jpg?rect=0%2C0%2C3900%2C2048&w=1200&auto=format%2Ccompress&ogImage=true)
Profit Protection Strategy: Tata Elxsi and Tata Consumer Products Under the Spotlight
![](https://pocket-image-cache.com/direct?url=http://bl-i.thgim.com/public/incoming/xxfoyh/article66156865.ece/alternates/LANDSCAPE_1200/IMG_IMG_PO22_Bull_bear_m_2_1_DL9RADQ1.jpg)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.27%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 0.44% to 0.61%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 32.62%, vs industry avg of 15.15%